Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on Aug 26, 2020 7:14pm
175 Views
Post# 31458168

RE:RE:RE:RE:RE:RE:RE:Taimed Limit up 10% on big volume

RE:RE:RE:RE:RE:RE:RE:Taimed Limit up 10% on big volume
As usual I am on the pessimist side. If I am Taimed, for 2 reasons I would think twice before giving Thera a second product to sell. First Thera do not deserve it. The were not able to sell Trogarzo. I understand the market was not exactly what Taimed was expecting but Thera should have known better. You can be wrong but not that much I would say. Second, I would prefer to have two different partners to give both some pressure to insure they do their best on selling their respective product knowing other product may have to be distribute in the future.
About Paul's comment on Trogarzo sells not reaching full potential, he has no choice of saying that. He had to show Taimed that he is not giving up on Trogarzo. He had to insure his only customer keep confidence that Thera is still working hard to improve sells even if Thera has other interesting plans in parallel that are taking a lot of time and energy to improve TH's future.
What a big surprise that would be but ... We are not there yet. We can only dream about Taimed possible succes on Covid drug AND about Thera to be lucky enought to get the deal from Taimed. I am saying lucky because again, they do not deserv it ... yet :o)
Bullboard Posts